For Research
The gold standard ’omics for the research community.

Nightingale Health sells single-sample blood tests detecting multiple chronic disease risks to healthcare providers and health platforms.
nightingalehealth.comCrawled Nov 10, 2026
The gold standard ’omics for the research community.
The most advanced remote health check for the health industry.
Innovation that doesn’t disrupt anything but changes everything.
Nightingale Health aims to improve health outcomes through industry transformation.
Nightingale Health’s technology appears in over 900 publications and supports epidemiological and genetic studies.
Nightingale Health develops sustainable healthcare solutions.
Nightingale Health offers services and business opportunities.
The most advanced health check for the health industry.
Nightingale Health expands its disease risk detection platform to the Netherlands via VitaHealth. The partnership integrates Nightingale’s AI-driven health analytics into VitaHealth’s services, enabling early disease risk assessment for Dutch consumers. The tool analyzes routine blood test data to identify potential health risks before symptoms appear.
Nightingale Health integrates its disease risk detection tools into annual health assessments at Barnes Private Practice in London. The partnership expands predictive health screening for patients undergoing routine check-ups. Barnes Private Practice adopts the technology to enhance early disease identification during standard evaluations.
Nightingale Health secures approval for its first laboratory-developed tests (LDTs) from New York State, marking a key regulatory milestone in the U.S. The company’s diagnostic tests now meet state requirements, expanding its operational footprint beyond its existing markets. This approval enables Nightingale Health to offer advanced testing solutions to healthcare providers in New York, a major market for medical diagnostics.
Nightingale Health Plc partners with S-Thetics to include its **Nightingale Health Check** in the UK-based **longevity membership program**, launching in November 2026. The agreement expands access to the company’s health assessment within S-Thetics’ subscription service. Financial details of the collaboration remain undisclosed.
Alamar Biosciences and Nightingale Health are leading an 80,000-sample study using UK Biobank data to advance research on neurodegenerative diseases. The initiative, backed by The Michael J. Fox Foundation, Alzheimer’s Research UK, and LifeArc, focuses on improving early detection, prevention, and treatment for Parkinson’s, Alzheimer’s, and rare dementias. The collaboration aims to leverage large-scale data analysis to uncover insights into disease progression and potential interventions.
Nightingale Health Plc partners with The Private GP Group to integrate its health check into annual GP assessments. The test provides 10-year risk estimates for five chronic diseases using a single blood sample. This expands access to predictive health screening for patients in the UK’s private healthcare sector.